Dominic Maxwell, MD
Psychiatry · Cambridge, MANPI 1134178106
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 27.8% of the total. Reporting peaked in 2022 at $606 and has fallen 80.5% since, to $118 in 2023.
Across 46 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$305
- Lundbeck LLC$190
- Otsuka America Pharmaceutical, Inc.$136
- Sunovion Pharmaceuticals Inc.$119
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$114
- Corium, LLC$75
- plus $157 from 5 others
Across 2 payments — averaging $6982.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceutical Holding Company Ltd.$14K
What the payments were for
- Food & beverage$1,097100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $305 |
| Lundbeck LLC | 10 | $190 |
| Otsuka America Pharmaceutical, Inc. | 6 | $136 |
| Sunovion Pharmaceuticals Inc. | 1 | $119 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $114 |
| Corium, LLC | 4 | $75 |
| Alkermes, Inc. | 3 | $71 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Tris Pharma Inc | 1 | $22 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LATUDA$119
How this compares
$1,097 in reported general payments places this provider in the 85th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 39 | $690 |
| Quetiapine Fumarate | 41 | $641 |
| Lamotrigine | 46 | $477 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $456 |
| Bupropion Hcl SrBupropion Hcl | 29 | $251 |
| Prazosin Hcl | 12 | $224 |
| Escitalopram Oxalate | 14 | $188 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $142 |
| Lorazepam | 46 | $119 |
| Sertraline Hcl | 24 | $69 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Cambridge
- Craig SurmanCambridge$111K
- Jennifer BrownCambridge$37K
- Theresa CerulliNorth Andover$724K
- Andrew AldridgeMedford$407K
- Amjad BahnassiWorcester$352K
- Ximena Sanchez-SamperBoston$258K
- Robert AlexanderBelmont$170K
- George PapakostasBoston$170K
- Xiangyang LiMilford$166K
- Ernesto ZilberbergNorth Andover$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.